Monique K. Mansoura
Biodefense专家从各个角度看到民族准备
Monique K. Mansoura,Ph.D., MBA, leads MITRE’s work in global health security and biotechnology. An expert in biodefense and drug development and policy, Mansoura credits several man-made and natural disasters with sharpening her resolve to find ways to reimagine how the U.S. prepares for and navigates major events like the COVID-19 pandemic.
My parents came to the U.S. from Germany and Egypt with hope for a better life, and I was raised to understand that education was a path to meaningful options. I had an affinity for science and math and was on autopilot to become an engineer like my dad. I was also an athlete and musician—being versatile was important to me. It helped me pivot to new opportunities, and it’s a survival skill for a career focused on preparing for worst-case scenarios.
大学毕业后，我在石油行业担任化学工程师。但这不是我一生的呼唤。我决定在密歇根大学学习生物工程，作为通往医学院的桥梁。作为骨科生物力学实验室的研究助理，我发现了对科学发现的热情。我更改了课程以获得博士学位。在生物工程中。
When I heardFrancis Collinsspeak about [what was then] a new scientific endeavor, the人类基因组项目, I was instantly drawn to the mission. The idea that we could engineer biology was transformational.
我从想要做出更好的膝盖替换关节（在垒球损伤之后）到想要翻译人类基因组以开发挽救生命的药物的方法。我对囊性纤维化的论文研究使我对药物开发的转化科学有无价的见解。
弗朗西斯·柯林斯（Francis Collins）成为国立卫生研究院后的论文顾问和导师。他告诉我，科学家有义务离开实验室，与人们谈论研究及其转变医学的希望。讨论人类基因组项目的道德，法律和社会影响至关重要。我们聘请了黑人教堂，纳瓦霍民族和其他主要社区，以听取人们的关注。
这种经验帮助我了解到有效的社区参与对于解决Covid-19疫苗犹豫至关重要。
确保生物制药供应链
（温柔的音乐开始）
- [Narrator] The coronavirus pandemic,
the great power competition, wide area wildfires,
and other major events heighten the vulnerabilities
in our nation's bio-pharmaceutical supply chains.
Securing and diversifying these supply chains
不仅是公共卫生和福祉的问题。
It's vital to our national security.
We need to strengthen the safety and security
of basic life-saving
and specialized medicines and equipment.
Weaknesses at any point in this critical infrastructure
威胁整个系统。
Shortages in any one area puts lives at risk.
- 我们发现的是触发短缺，
in large part exacerbated by the COVID-19 pandemic,
that 29 out of 40 critical drugs
保存和保护和挽救生命所需的
现在处于严重的短缺。
与我们作为一个国家准备的其他威胁不同，
nuclear threat, cyber attack, others,
this is a near-simultaneous global event.
- [Narrator] Industrial-based policy
and innovative business models are needed
重新调整激励措施并实现必要的生产
to strengthen the bioeconomy
并实现国家安全目标。
- 现在需要
对于斜切带来的优势和能力。
Again, our systems thinking,
our deep expertise in supply chain risk management,
our understanding and the trusted relationships
we've established with the bio-pharmaceutical industry,
to be a neutral, independent arbiter,
understanding that there are differences
between the public health and the industrial communities.
- [Narrator] Developing solutions
to secure bio-pharmaceutical supply chains
是Miter解决问题的任务的一部分
对于一个更安全的世界。
（温柔的音乐结束）
Preparedness as a National Security-Public Health Relationship
The anthrax attacks after 9/11 showed us that these threats are real, we were vulnerable, and the country and the scientific community were unprepared. I went to HHS [the Department of Health and Human Services] to help develop medical countermeasures. I met brilliant and dedicated public servants there. I joined for a 30-day detail and stayed nine years. It was a remarkable opportunity to build an organization [the生物医学高级研发局] that’s central to our nation’s pandemic response.
20年后，我们正在就对策和准备进行类似的讨论。但是现在，我更加完全感谢这项任务的复杂性。
We saw shortages of saline and other critical drugs after Hurricane Maria devastated Puerto Rico in 2017. Now the pandemic, unlike any other recent event, has highlighted the vulnerabilities in our生物制药供应链和生物工业政策。
我们必须做得更好，以准备可能破坏药物使用并引发医疗对策需求的潮流的威胁。网络，恶劣天气，贸易争端以及自然发生，意外或故意生物学事件等威胁。
米特（Miter）对这一大流行的反应令人鼓舞，我很荣幸能成为COVID-19 Healthcare Coalition. We’ve engaged over 1,000 partners to build the capabilities needed so that we’ll never again see what has played out this past year. We’ve already学到很多.
发展生物经济的新模型
After many years leading strategy and policy in federal medical countermeasures, I realized that we didn’t have ascience问题;我们有一个businessproblem.
Free markets are economically efficient to optimize financial success and require leaders in health and national security to be innovative in establishing the capabilities and capacities required. Driving resilience to drug shortages and enhancing biopreparedness from threats like SARS-CoV-2 will require novel business models and financing strategies—as we’ve seen withcivicarxand proposed for全球卫生安全.
我离开政府获得了MBA（在麻省理工学院）学习生物制药发展的业务方面。当我加入一家主要制药公司从事大流行准备工作时，我坐在公私合作伙伴关系的另一端。
改变我们的模型对于基本和挽救生命的药物和设备的安全，保障和可用性至关重要。将合理的工业基础政策和评估用于制造必需药物，医疗对策和医疗用品。作为原材料或活跃的药品成分和医疗用品的来源，在国外过度依赖，这使我们非常容易受到干扰。这些管道是我们关键基础设施和国防的核心。
The Power of Diversity
Studies show that women and people of color are underrepresented in science. That’s not good for science or society. We know from genomics that there’s strength in diversity. I’m happy MITRE fosters diversity and inclusion.
I came here three-and-a-half years ago after being invited to a MITRE-sponsored event about developing a national strategy for biomedical innovation. Light bulbs went off during our discussions. I love the systems approach we take to challenges and the access to talented scientists and technologists in the hard sciences and social sciences. I’m excited about the diverse team we’re building in global health security.
我一生中有很多冠军和导师。这就是为什么我致力于向年轻专业人士付款的原因。我鼓励每一次机会都听到不同的声音。
—as told to Karina Wright
加入我们的创新者，学习者，知识共同和冒险者社区。查看我们的职位空缺.